FIELD: medicine, biotechnology.
SUBSTANCE: invention relates to antibodies specifically binding to new human extracellular matrix polypeptides called as RGI; immunoconjugate containing the same and method for selective cell degradation; method for treatment of prostates cancer and metastasis in patients suffering from prostates cancer.
EFFECT: new method for treatment of prostates cancer.
28 cl, 7 ex, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| POLYNUCLEOTIDE MODULATING CANCER CELL PROLIFERATION (VARIANTS), POLYPEPTIDE, MONOCLONAL ANTIBODY, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL AGENT FOR TREATMENT OF PROLIFERATIVE DISEASE, PHARMACEUTICAL COMPOSITION, POLYPEPTIDE USES IN PHARMACEUTICAL AGENT PRODUCTION | 2002 |
|
RU2307666C2 |
| TUMOR POLYPEPTIDE ISOLATED FROM PROSTATE AND POLYNUCLEOTIDE ENCODING THEREOF | 1999 |
|
RU2234942C2 |
| DPPIV-COGNATED NEW SERINE PROTEASE GENE | 2001 |
|
RU2305133C2 |
| IMMUNITY-INDUCING AGENT | 2012 |
|
RU2634862C2 |
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| ANTIBODIES RECOGNISING EPITOPE ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS AND METHODS FOR USING THEM | 2008 |
|
RU2528738C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| METHOD FOR MAKING RECOMBINANT HETEROCARPINE | 2003 |
|
RU2359033C2 |
| NEW ISOFORMS OF VASCULAR ENDOTHELIAL CELL GROWTH INHIBITOR | 2002 |
|
RU2316591C2 |
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
